DR. BROOKE E BRANDER DO NPI 1083838239

NPI Details

DR. Brooke E Brander, DO is a hematology and oncology internal medicine in Fayetteville, AR with 21 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Brooke E Brander, DO NPI is 1083838239. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: OHIO UNIVERSITY, COLLEGE OF OSTEOPATHIC MEDICINE
Graduation Year:2005

The provider's business location address is:

3232 N NORTHHILLS BLVD
FAYETTEVILLE, AR
ZIP 72703-005
Phone: (479) 587-1700
Fax: (479) 587-1366

The NPI 1083838239 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1561)
• Injection, testosterone cypionate, 1 mg (HCPCS:J1071)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, gadoterate meglumine, 0.1 ml (HCPCS:A9575)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS:J0129)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, rituximab-abbs, biosimilar, (truxima), 10 mg (HCPCS:Q5115)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Magnesium level (HCPCS:83735)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Uric acid level, blood (HCPCS:84550)
• Bilirubin level, direct (HCPCS:82248)
• Phosphate level (HCPCS:84100)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, infliximab, excludes biosimilar, 10 mg (HCPCS:J1745)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg (HCPCS:Q5108)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Measurement of substance using immunoassay technique (HCPCS:83520)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Ct scan of abdomen and pelvis before and after contrast (HCPCS:74178)
• Ct scan of chest with contrast (HCPCS:71260)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Vitamin d-3 level (HCPCS:82306)
• Unclassified drugs (HCPCS:J3490)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Measurement c-reactive protein for detection of infection or inflammation (HCPCS:86140)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month (HCPCS:99490)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Blood test, clotting time (HCPCS:85610)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Manual urinalysis test with examination using microscope, non-automated (HCPCS:81000)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Folic acid level, serum (HCPCS:82746)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Cortisol (hormone) measurement, total (HCPCS:82533)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Ct scan of chest without contrast (HCPCS:71250)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Ct scan of abdomen and pelvis without contrast (HCPCS:74176)
• Mri scan of brain before and after contrast (HCPCS:70553)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• X-ray of chest, 2 views (HCPCS:71046)
• Hospital discharge day management, 30 minutes or less (HCPCS:99238)
• Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month (HCPCS:99439)
• Injection, furosemide, up to 20 mg (HCPCS:J1940)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Thyroxine (thyroid chemical), total (HCPCS:84436)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) (HCPCS:G0506)
• Glutamyltransferase (liver enzyme) level (HCPCS:82977)
• Injection of drug or substance into vein (HCPCS:96374)
• Drawing of blood for a medical problem (HCPCS:99195)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Injection, meperidine hydrochloride, per 100 mg (HCPCS:J2175)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Adm sarscov2 30mcg/0.3ml bst (HCPCS:0004A)
• Ct scan of head or brain before and after contrast (HCPCS:70470)
• Fee covid-19 vac 14 res (HCPCS:0134A)
• Nuclear medicine study whole body with ct scan (HCPCS:78816)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Ultrasound of heart with color-depicted blood flow, rate, direction and valve function (HCPCS:93306)
• Blood creatinine level (HCPCS:82565)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Heart muscle strain imaging (HCPCS:93356)

The enumeration date for this NPI number is 4/12/2007 and was last updated on 1/31/2024.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.